Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Binimetinib (Primary) ; Pembrolizumab
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Nov 2017 Planned End Date changed from 1 May 2020 to 15 May 2020.
- 29 Nov 2017 Planned primary completion date changed from 1 May 2020 to 15 May 2020.
- 27 Sep 2017 Status changed from not yet recruiting to recruiting.